[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1068207A1 - DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE - Google Patents

DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE

Info

Publication number
EP1068207A1
EP1068207A1 EP99916294A EP99916294A EP1068207A1 EP 1068207 A1 EP1068207 A1 EP 1068207A1 EP 99916294 A EP99916294 A EP 99916294A EP 99916294 A EP99916294 A EP 99916294A EP 1068207 A1 EP1068207 A1 EP 1068207A1
Authority
EP
European Patent Office
Prior art keywords
methyl
indole
trimethylphenyl
amino
pyridino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99916294A
Other languages
German (de)
English (en)
Inventor
Raymond F. Horvath
James W. Darrow
George D. Maynard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of EP1068207A1 publication Critical patent/EP1068207A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to aminoalkyl substituted 9H-pyridino [2, 3-b] indole and 9H-pyrimidino [4 , 5-b] indole derivatives which selectively bind to corticotropin-releasing factor (CRF]_) receptors and to mammalian neuropeptide Y (NPY ] _) receptors. It further relates to pharmaceutical compositions containing such compounds and the use of such compounds in treating physiological disorders induced or facilitated by CRF or those associated with an excess of neuropeptide Y.
  • CRF corticotropin-releasing factor
  • Corticotropin releasing factor (herein referred to a ⁇ CRF) , a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland [J. Rivier et al . , Proc . Na t . Acad . Sci . (USA) 80:4851 (1983); . Vale et al . , Science 213:1394 (1981)].
  • POMC proopiomelanocortin
  • CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders.
  • CRF cerebral spinal fluid
  • CRF produces anxiogenic effects in animals and interactions between benzodiazepine /
  • CRF cardiovascular or heart-related diseases such as hypertension, tachycardia and congestive heart failure, stroke and osteoporosis.
  • CRF has also been implicated in premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus and colonic hypersensitivity associated with psychopathological disturbance and stress.
  • Neuropeptide Y a peptide first isolated in 1982, is widely distributed in the central and peripheral neurons and is responsible for a multitude of biological effects in the brain and the periphery.
  • Various animal studies have shown that activation of neuropeptide NPYi receptors is related to vasoconstriction, Wahlestedt et al . , Regul . Peptides, 13_: 307- 318 (1986), McCauley and Westfall, J. Pharmacol . Exp . Ther. 261: 863-868 (1992), and Grundemar et al . , Br. J. Pharmacol .
  • This invention provides novel compounds of Formula I which interact with CRF ⁇ receptors and NPY ⁇ receptors. It further relates to the use of such compounds, pharmaceutical compositions comprising these compounds, and methods useful for the treatment of psychiatric and affective disorders and neurological diseases, including major depression, headaches, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy, as well as treatment of immunological, cardiovascular or heart-related diseases, hypertension, feeding disorders, diabetes, dislipidemia, colonic hypersensitivity associated with psychopathological disturbance, and stress. It further relates to the use of such compounds in treating physiological disorders induced or facilitated by CRF or those associated with an excess of neuropeptide Y.
  • this invention provides aminoalkyl substituted 9H-pyridino [2 , 3- b] indole and 9H-pyrimidino [4 , 5-b] indole derivatives of Formula
  • CRF ⁇ mammalian neuropeptide Y receptors and/or to mammalian neuropeptide Y (NPY ] _) receptors.
  • Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, carboxamido, N-lower alkyl carboxamido, N,N-lower dialkyl carboxamido, Ci-C ⁇ alkyl, Ci-C ⁇ alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;
  • R is hydrogen, halogen, trifluoromethyl , C ⁇ -C6 alkyl, or (C ⁇
  • 3 3 W is N or C-R where R is hydrogen or C ⁇ -C6 alkyl
  • V and V are CH2 , CO, CS, SO2 or CH(C_-C6 alkyl), with
  • Y and Y independently represent a bond or C]_-C6 alkylene
  • A is NR R wherein R and R are independently hydrogen, a lower alkyl group which optionally forms
  • R and R cannot both be alkanoyl or alkylsulfonyl
  • N 1 wherein e and f are independently 1, 2 or 3 and the sum of e and f is at least 3;
  • R is hydrogen or C ⁇ Cg alkyl
  • R is hydrogen or C ⁇ -C6 alkyl; C ⁇ -C ⁇ arylalkyl or C -C6 heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substitu
  • G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -C6 alkyl
  • heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-,
  • 2- or 5-tetrazolyl each of which is optionally mono- or disubstituted with halogen, trifluoromethyl , amino, C ⁇ -C6 alkyl, C ⁇ -C6 alkoxy, with the proviso that tetrazolyl can have at most one substituent ;
  • Z is carbon or nitrogen; where when Z 2 is CH, n is 0, 1, 2 or 3 and p is 1, 2, or 3,
  • R is carboxamido, or (Crj-C6 alkylene) -G -R
  • G is NH, NH(C ⁇ -C6 alkyl) and R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl , and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent
  • N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl , each of which is optionally substituted with amino, trifluoromethyl, carboxamido, or (C ⁇ -C6
  • R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl, 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl
  • the compounds of Formula I are antagonists at the CRFx receptor and are useful in the diagnosis and treatment of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.
  • stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.
  • psychiatric and affective disorders and neurological diseases including major depression, headaches, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy, as well as treatment of immunological, cardiovascular or heart - related diseases, hypertension, feeding disorders, diabetes, dislipidemia, colonic hypersensitivity associated with psychopathological disturbance, and stress.
  • Such methods involve administration to a mammal of an effective amount of a compound of the invention.
  • the compounds of Formula I are also neuropeptide Y ] _ receptor antagonists, and, therefore, are also of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of neuropeptide Y.
  • the compounds of Formula I have different chemical structures which affect their selectivity towards either the CRFx or the
  • NPYx receptors NPYx receptors
  • Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, carboxamido, N-lower alkyl carboxamido, N,N-lower dialkyl carboxamido, C ⁇ -C6 alkyl, C ⁇ -C6 alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;
  • R is hydrogen, halogen, trifluoromethyl, C ⁇ -Cg alkyl, or (C ⁇
  • W is N or C-R where R is hydrogen or C ⁇ -C6 alkyl
  • V and V are CH2 , CO, CS, SO2 or CH(C ⁇ -C6 alkyl), with
  • Y and Y independently represent a bond or C ⁇ -C ⁇ alkylene
  • R and R are independently hydrogen, a lower alkyl group which optionally forms
  • heterocycloalkyl group with Y C ⁇ -C6 arylalkyl or C ⁇ -Cg heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl , 1- , 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl or hetero
  • R and R cannot both be alkanoyl or alkylsulfonyl
  • N 1 wherein e and f are independently 1, 2 or 3 and the sum of e and f is at least 3;
  • R is hydrogen or C ⁇ C g alkyl
  • C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl where aryl is phenyl , and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl or heterocycloalkyl ring;
  • G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -C6 alkyl
  • heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-,
  • Z is C ⁇ -C6 alkyl
  • R is carboxamido, or (C0-C6 alkylene) -G -R
  • G is NH, NH(C ⁇ -C6 alkyl) and R is hydrogen, C_,_-C6 alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl , and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent
  • N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with amino, trifluoromethyl, carboxamido, or (C ⁇ -C6
  • R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl , where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl , 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloal
  • ⁇ 16- Preferred compounds of Formula I include those of Formula
  • each R a is C ⁇ Cg alkyl;
  • R b is hydrogen or methyl;
  • R- L is C ⁇ Cg alkyl;
  • R s is Ci-Cg alkyl, (C 3 -C 5 ) cycloalkyl (C 1 -C 3 ) alkyl, (C 1 -C 3 ) alkoxy (C - C 3 ) alkyl, or (C 3 -C 5 ) cycloalkyl ;
  • t is 1, 2 or 3;
  • R x is hydrogen, C ⁇ Cg alkyl, phenyl (C ⁇ Cg) alkyl where phenyl is optionally mono- or disubstituted independently with Ci-C 6 alkyl, C ⁇ Cg alkoxy, halogen, or hydroxy; and R y is hydrogen, C ⁇ -C 6 alkyl, (C 3 -C 6 ) cycloalkyl ; or
  • NR x R y represents pyrrolidinyl, N- (Ci-C 6 ) alkylpyrrolidin-2-yl , piperidinyl, morpholinyl, or N- (C ⁇ -C 6 ) alkylpiperazinyl .
  • Preferred compounds of Formula IA include those where R s is Ci-Cg alkyl or cyclopropylmethyl. Other preferred compounds of Formula IA include those where R s is cyclopropyl (Ci-C 3 ) alkyl . Still other preferred compounds of Formula IA include those where R x and R y independently represent hydrogen or Ci-C 2 alkyl. More preferred compounds of IA include those where R s is cyclopropyl (C 1 -C 3 ) alkyl, R x and R y independently represent hydrogen or C x -C 2 alkyl; and each R a is methyl. Particularly preferred compounds of IA are those W is nitrogen.
  • each R a is C 1 -C 6 alkyl ; Ri is Ci-Cg alkyl ; R s is Ci-Cg alkyl , cyclopropyl (Ci-C 3 ) alkyl or (Ci ⁇ C 3 ) alkoxy ( C x -
  • R x is hydrogen, Ci-C 6 alkyl , phenyl (C ⁇ Cg) alkyl where phenyl is optionally mono- or disubstituted independently with C ⁇ -C 6 alkyl , Ci-C 6 alkoxy, halogen, or hydroxy; and R y is hydrogen, Ci-C 3 alkyl , (C 3 -C 6 ) cycloalkyl ; or
  • NR x R y represents pyrrolidinyl , N- (Ci-C 3 ) alkylpyrrolidin-2 -yl , piperidinyl , morpholinyl , or N- (C ⁇ Cg) alkylpiperazinyl .
  • Preferred compounds of Formula IB include those where R s is Ci-Cg alkyl or cyclopropylmethyl. Other preferred compounds of Formula IB include those where R s is cyclopropyl (Ci-C 3 ) alkyl . Yet other preferred compounds of Formula IB include those where t is 1 and R x and R y independently represent hydrogen or C ⁇ -C 2 alkyl . More preferred compounds of Formula IB include those where R s is cyclopropyl (Ci-C 3 ) alkyl , t is 1 and R x and R y independently represent hydrogen or Ci-C 2 alkyl.
  • Particularly preferred compounds of IB are those where each R a is methyl, R s is cyclopropyl (Ci-C 3 ) alkyl , t is 1 and R x and R y independently represent hydrogen or Ci-C 2 alkyl.
  • Highly preferred compounds of Formula IB are those where W is nitrogen.
  • Other preferred compounds of Formula I include those of Formula IC:
  • each R a is C ⁇ -C 6 alkyl
  • Ri Ci-Cg alkyl ; t is 1 or 2 ;
  • Preferred compounds of Formula IC include those wherein R 1 is Ci-C 2 alkyl and W is nitrogen. Other preferred compounds of IC are those where each R a is methyl and W is nitrogen.
  • each R a independently represents Ci.C 6 alkyl
  • R is hydrogen, halogen, trifluoromethyl , C -C6 alkyl, or (C ⁇
  • V and V are CH2 , CO, CS, SO2 or CH(C ⁇ -C6 alkyl), with
  • Y and Y independently represent a bond or C ⁇ -C6 alkylene
  • 1 4 5 , 4 5 A is NR R wherein R and R are independently hydrogen, a lower alkyl group which optionally forms
  • C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1- , 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents
  • -20- can together form a 5-7 fused cycloalkyl or heterocycloalkyl ring; lower alkanoyl, lower alkylsulfonyl, with the proviso
  • R and R cannot both be alkanoyl or alkylsulfonyl
  • N 1 wherein e and f are independently 1, 2 or 3 and the sum of e and f is at least 3;
  • R is hydrogen or Ci-C 6 alkyl
  • C ⁇ -C6 arylalkyl or C ⁇ -C ⁇ heteroarylalkyl where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl , hydroxy, amino, lower alkylamino, lower dialkylamino, lower
  • G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -C6 alkyl
  • heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono- or disubstituted with halogen, trifluoromethyl , amino, C ⁇ -C6 alkyl, C -C6 alkoxy, with the proviso that tetrazolyl can have at most one substituent ;
  • Z is C ⁇ -C6 alkyl
  • V , Y and A are as defined above;
  • Z is carbon or nitrogen
  • R is carboxamido, or (C0-C6 alkylene) -G -R
  • G is NH, NH(C ⁇ -C6 alkyl) and R is hydrogen, C ⁇ -C6 alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl s phenyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substitu
  • N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with amino, trifluoromethyl , carboxamido, or (C ⁇ -C6
  • R is hydrogen, C ⁇ -C6 alkyl, C ⁇ -C ⁇
  • aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl or heterocycloalkyl ring.
  • Preferred compounds of Formula II are those where V 1 and
  • V 2 represent methylene; Y 1 is a bond; A 1 represents pyrrolidinyl, morpholinyl; piperazinyl, mono- or di-Ci-C 6 alkyl, C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4-imidazolyl , 2-, 4-, or 5-oxazolyl, 2-,
  • Y 2 represents a bond or methylene; and A 2 represents C ⁇ C g alkyl or Ci-C 8 alkoxymethyl .
  • each R a independently represents C ⁇ C g alkyl
  • R is hydrogen, halogen, trifluoromethyl , C ⁇ -C6 alkyl, or (C ⁇
  • V and V are CH2, CO, CS, SO2 or CH(C ⁇ -C6 alkyl), with
  • Y and Y independently represent a bond or C -C ⁇ alkylene
  • A is NR R wherein R and R are independently hydrogen, a lower alkyl group which optionally forms
  • heterocycloalkyl group with Y C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1- , 3- or 4-pyrazolyl, 1-, 3- or 4-
  • R and R cannot both be alkanoyl or alkylsulfonyl
  • R is hydrogen or C ⁇ C g alkyl
  • CONH2 CO[N(C ⁇ -C6 alkyl )R ] wherein R is hydrogen or C ⁇ -C6 alkyl; C ⁇ -C6 arylalkyl or C ⁇ -C6 heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl , 1-, 2- or 4-
  • A is hydrogen, C ⁇ -Cg alkyl, (C ⁇ -Cg alkylene) -G -R
  • G is oxygen or sulfur and R is hydrogen, trifluoromethyl or C ⁇ -Cg alkyl
  • heteroaryl is 2-, 3- or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4 -imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4-triazolyl, 2-pyrazinyl, or 1-,
  • 2- or 5-tetrazolyl each of which is optionally mono- or disubstituted with halogen, trifluoromethyl , amino, C ⁇ -Cg alkyl, C ⁇ -Cg alkoxy, with the proviso that tetrazolyl can have at most one substituent ;
  • Z is C ⁇ -Cg alkyl
  • V , Y and A are as defined above;
  • Z is carbon or nitrogen; where when Z 2 is CH, n is 0, 1, 2 or 3 - and p is 1, 2, or 3,
  • R is carboxamido, or (Cn-Cg alkylene) -G -R
  • G is NH, NH(C ⁇ -Cg alkyl) and R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -Cg arylalkyl or C ⁇ -Cg heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4-pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4 -imidazolyl, 2-, 4-, or 5- oxazolyl, 2-, 4-, or 5 -thiazolyl, 1-, 3- or 4- pyrazolyl, 1-, 3- or 4 -triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl , each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the provis
  • N-ring represents triazolyl, tetrazolyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with amino, trifluoromethyl, carboxamido, or (C ⁇ -Cg
  • R is hydrogen, C ⁇ -Cg alkyl, C ⁇ -Cg arylalkyl or C ⁇ -Cg heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4- pyridyl, 2-, 4- or 5-pyrimidinyl, 1-, 2- or 4- imidazolyl, 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5- thiazolyl, 1-, 3- or 4 -pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5- tetrazolyl, each of which is optionally mono-, di-, or tri-substituted with halogen, trifluoromethyl, hydroxy, amino, lower alkylamino, lower dialkylamino, lower alkylcarboxamido, lower alkyl, lower alkoxy, with the proviso that 2 adjacent substituents can together form a 5-7 fused cycloalkyl,
  • Preferred compounds of Formula III are those where V 1 and V 2 represent methylene; Y 1 is a bond; A 1 represents pyrrolidinyl, morpholinyl; piperazinyl, mono- or di-Ci-C 6 alkyl, C ⁇ -Cg arylalkyl or C ⁇ -Cg heteroarylalkyl, where aryl is phenyl, and heteroaryl is 2-, 3-, or 4 -pyridyl, 2-, 4- or 5- pyrimidinyl, 1-, 2- or 4 - imidazolyl , 2-, 4-, or 5-oxazolyl, 2-, 4-, or 5-thiazolyl, 1-, 3- or 4-pyrazolyl, 1-, 3- or 4- triazolyl, 2-pyrazinyl, or 1-, 2- or 5-tetrazolyl , each of
  • Preferred compounds of the invention include: 4- (N- (2-N' ,N' -Dimethylaminoethyl) -N-ethyl) amino-2 -methyl - 9- (4-bromo-2 , 6-dimethylphenyl) -9H-pyrimidino [4 , 5-b] indole
  • the compounds of Formula I may contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms.
  • These compounds can be, for example, racemates or optically active forms.
  • the single enantiomers, i.e., optically active forms can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such
  • Representative compounds of the present invention include, but are not limited to the compounds in Table I and their pharmaceutically acceptable acid addition salts.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt, particularly a pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds .
  • Non-toxic pharmaceutical salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH 2 )n-COOH where n is 0-4, and the like.
  • acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC- (CH 2 )n-COOH where n is 0-4, and the like.
  • the present invention also encompasses the acylated prodrugs of the compounds of Formula I.
  • acylated prodrugs of the compounds of Formula I Those skilled in the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula I .
  • alkyl straight or branched chain alkyl groups having 1-6 carbon atoms optionally forming a 3 to 6 atoms carbocycle, such as, for example, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclopropylmethyl, n-butyl, sec-butyl, tert-butyl, cyclobutyl, pentyl, 2-pentyl, i'sopentyl, neopentyl,
  • Co-Cg alkylene is meant a direct bond or a C ⁇ -Cg alkylene group, optionally forming a 3 to 6 atoms carbocycle, such as methylene, ethylidene, propylidene, butylidene, pentylidene, cyclopentylidene, hexylidene, cyclohexylidene.
  • alkoxy straight or branched chain alkoxy groups having 1-6 carbon atoms optionally forming a 3 to 6 atoms carbocycle, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, cyclopropylmethoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, cyclopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, cyclohexoxy.
  • alkanoyl straight or branched chain alkanoyl groups having 1-6 carbon atoms optionally forming a 3 to 6 atom carbocycle, such as, for example, acetyl, propionyl, isopropionyl, cyclopropionyl, butanoyl, pentanoyl, cyclopentanoyl, hexanoyl, cyclhexanoyl .
  • the " ⁇ -position" of the alkanoyl groups herein is the terminal carbon atom.
  • CONH represents an amide functional group, i.e., O
  • heterocycle or “heterocycloalkyl” means a monocyclic or bicyclic hydrocarbon group which in which one or more of the ring carbon atoms has been replaced with a heteroatom, e.g., oxygen, sulfur or nitrogen. Such groups preferably have 4 to 10 carbon atoms and 1 to 4 heteroatoms .
  • halogen in the present invention is meant fluorine, bromine, chlorine, and iodine.
  • the compounds of general Formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier.
  • One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.
  • compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an i-nert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an i-nert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters
  • aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachid oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending age-.c and one or more preservatives.
  • a dispersing or wetting agent suspending age-.c and one or more preservatives.
  • Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachid oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation
  • emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono-or diglycerides .
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of general Formula I may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • Compounds of general Formula I may be administered parenterally in a sterile medium.
  • the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
  • adjuvants such as
  • Dosage levels of the order of from about 0. l ⁇ mg to about 140Umg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5Umg to about 7Ug per patient per day) .
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • Dosage unit forms will generally contain between from about l ⁇ mg to about 500Umg of an active ingredient.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • THF refers to tetrahydrofuran.
  • LDA refers to lithium diisopropylamide and DDQ refers to 2 , 3-dichloro-5 , 6-
  • Example 1 A. 2 -Amino-4 ,5,6, 7 -tetrahydro-1 -phenyl -lH-indole-3- carbonitrile
  • Example IA To the product of Example IA (535 g) dissolved in dichloroethane (4 L) are added 2-methoxypropene (550 mL) and p- toluenesulfonic acid monohydrate (3.6 g) . The mixture is refluxed for 1 hour then the solvent is removed by distillation. The residue is dissolved in THF (3 L) and cooled to 0°C. To this solution, under an atmosphere of nitrogen gas, is added LDA (2.0M, 1.2 L) at a rate to keep the reaction's internal temperature below 10°C. After 3 hours the reaction is neutralized with aqueous HCl. The aqueous layer is extracted with ethyl acetate and combined with the THF layer.
  • 2-methoxypropene 550 mL
  • p- toluenesulfonic acid monohydrate 3.6 g
  • the mixture is refluxed for 1 hour then the solvent is removed by distillation.
  • the residue is dissolved in THF (3 L) and
  • Example IB The product of Example IB (600 g) is dissolved in decahydronaphthalene (4 L) and heated to distill off low boiling impurities that are present. The solution is cooled to ambient temperature and charged with 10% Palladium on Carbon
  • a steel bomb containing the product from Example IE (61 g) , pyrrolidine (60 mL) and N-methylpyrrolidinone (250 mL) is sealed and heated to 120°C for 5 hours.
  • the mixture is poured into water and extracted with ethyl acetate.
  • the organic layer is washed with water, dried over sodium sulfate, filtered and concentrated.
  • the product is purified by flash chromatography. First 100% ethyl acetate is used to elute impurities followed by 10% methanol in dichloromethane to elute the desired product. Obtain 60 g of compound that crystallizes on standing.
  • the sulfate salt of the amine is formed by adding concentrated sulfuric acid (2.44 mL) to amine (21.4 g) dissolved in ethanol (50 mL) . Isopropanol (200 mL) is added to the ethanol solution at reflux. Crystals of sulfate that form on cooling are collected by filtration and washed with cold isopropanol: MS (free base) 467 (M+H).
  • Example 2 The following compounds are prepared essentially according to the procedures set forth above in Example 1. a) 4- (N- (2-N' ,N' -Dimethylaminoethyl) -N-propyl) amino-2- methyl-9- (2,4, 6 -trimethylphenyl) -9H-pyridino [2, 3-b] indole: MS 429 (M+H) . (Compound 2)
  • Example 9 The following compounds are prepared essentially according to the procedure set forth in Example 8.
  • Example 11 The following compounds are prepared essentially according to the procedure set forth in Example 10. a) 4- (N- (2-Pyrrolidinoethyl) -N- cyclopropyloxomethyl) amino-2 -methyl -9- (2,4, 6-trimethylphenyl) - 9H-pyridino [2,3-b] indole: MS 481 (M+H). (Compound 69)
  • Example 13 The following compounds are prepared essentially according to the procedure of Example 12. a) 4- (N- (2 -N' ,N' -Dimethylamino-2 -oxoethyl ) -N-2 - methoxyethyl) amino-2 -methyl -9- (2,4, 6 -trimethylphenyl) -9H- pyridino [2, 3-b] indole: MS 459 (M+H). (Compound 72)
  • Example 16 The following compounds are prepared essentially according to the procedures set forth above in Example 15.
  • Example 17 A. 2 -Amino- 1 -phenyl -1H- indole-3 -carbonitrile
  • Example 12B The compound from Example 12B (2.2 g) is refluxed in phosphoryl chloride (30 mL) for 3 hours. The excess phosphoryl chloride is removed under reduced pressure and the residue is partitioned between aqueous potassium carbonate and dichloromethane. The aqueous is extracted with more dichloromethane. The combined extracts are dried over sodium sulfate, filtered and concentrated to give a tan colored solid: MS 336 (M+H) .
  • Example 18 The following compounds are prepared essentially according to the procedure of Example 17.
  • Example 19 The pharmaceutical utility of compounds of this invention is indicated by the following assays for human CRF1 and NPYI receptor activity. Assay for CRF Receptor Binding Activity
  • CRF receptor binding is performed using a modified version of the assay described by Grigoriadis and De Souza (Methods in Neurosci ences, Vol. 5, 1991) .
  • Membrane pellets containing CRF receptors are re-suspended in 50mM Tris buffer pH 7.7 containing 10 mM MgCl2 and 2 mM EDTA and centrifuged for 10 minutes at 48000g. Membranes are washed again and brought to a
  • binding buffer Tris buffer above with 0.1 % BSA, 15 mM bacitracin and 0.01 mg/mL aprotinin
  • 100 mL of the membrane preparation is added to 96 well microtube plates containing 100 mL of 1 25I-CRF (SA 2200 Ci/mmol, final concentration of 100 pM) and 50 mL of drug. Binding is carried out at room temperature for 2 hours. Plates are then harvested on a Brandel 96 well cell harvester and filters are counted for gamma emissions on a Wallac 1205 Betaplate liquid scintillation counter. Non specific binding is defined by 1 mM cold CRF.
  • I 50 values are calculated with the non-linear curve fitting program RS/1 (BBN Software Products Corp., Cambridge, MA) .
  • the binding affinity for the compounds of Formula I expressed as IC50 value generally ranges from about 0.5 nanomolar to about 10 micromolar.
  • the binding activity of the compounds of formula I to the human CRF receptor can be measured as follows : Assay for Human CRF Receptor Binding Activity in IMR32 cells
  • IMR-32 human neuroblastoma cells are grown to 80% confluence in EMEM containing Earle's Balanced Salts and 2 mM 1 -glutamine with 10% FBS, 25 mM HEPES, 1 mM Sodium Pyruvate, and nonessential amino acids. At this time, flasks of cells are treated with 2.5 ⁇ M 5-bromo-2 ' -deoxyuridine (Br-dU) for 10 days. Media is changed every 3-4 days across the 10 day period. Cells are harvested using No-Zyme (JRH Biosciences) and rinsed with PBS. For membrane preparation, cells are homogenized in wash buffer (50 mM Tris HCl, 10 mM
  • -81- is performed using assay buffer (50 mM Tris HCl, 10 mM MgCl 2 , 2 mM EGTA, pH 7.4 , 0.1% BSA, 0.1 mM bacitrac (22.0mg/l00 mL) ) , 150 ⁇ g protein/tube, and [ 125 I] Sauvagine (NEN; 100 pM for competition analysis and 10 pM-1 nM for saturation analysis) to yield a final volume of 200 ⁇ L.
  • Nonspecific binding is defined using 2 ⁇ M r/h CRF or 9-41 alpha-helical CRF. Cells are incubated for 2 hours at room temperature.
  • the assay is terminated by rapid vacuum filtration (Tomtec: Deepwell 3) through GFC filters presoaked in 1% PEI using ice-cold 50 mM Tris HCl and dry thoroughly by air.
  • Specific Binding 70-80%; Kd (nM) : 0.30 nM; Bmax (fmole/mg protein): 40-50.
  • IC50 values are calculated with the non-linear curve fitting program RS/l (BBN Software Products Corp., Cambridge, MA) .
  • the binding affinities for the compounds of Formula I towards the 0RF ⁇ receptor are expressed as IC50 values and are less than 10 micromolar.
  • Compounds are assayed for activity using the following method: Baculovirus-infected Sf9 cells expressing recombinant human NPY Yl receptors are harvested at 42-48 hours at which time batches of 500 mL of cell suspension are pellete ⁇ by centrifugation.
  • Each pellet is re-suspended 30 mL of lysis buffer (10 mM HEPES, 250 mM sucrose, 0.5 ⁇ g/mL leupeptin, 2 ⁇ g/mL Aprotonm, 200 ⁇ M PMSF and 2.5 mM EDTA, pH 7.4 and gently homogenized by 50 strokes using a dounce homogenizer
  • the homogenate is centrifuged at 4°C for 10 minutes at 536 x g to pellet the nuclei.
  • the supernatant is collected into a fresh tube and centrifuged twice in the same buffer at 48,000 x g for 40 minutes.
  • the final pellet is subsequently re-suspe ⁇ e ⁇ 10 L of PBS containing 5 mM EDTA by dounce homogenization and stored m aliquots at -80°C.
  • NPY [ 125I] NPY (porcine) for saturation analysis.
  • GTP is added at a final concentration of 100 ⁇ M.
  • Cold displacers are added at concentrations ranging from 10 - ⁇ 2 M to 10 6 M to yield a final volume of 0.250 mL.
  • Nonspecific binding is determined in the presence of 1 ⁇ M NPY (human) and accounts for less than 10% of total binding.
  • the reaction is terminated by rapid vacuum filtration. Samples are filtered over presoaked GF/C Whatman filters (1.0% polyethyleneimine for 2 hours) and rinsed 2 times with 5 mL cold binding buffer lacking BSA. Remaining bound radioactivity is measured by gamma counting. To estimate the Bmax, Kd and Ki , the results of binding experiments are analyzed using SigmaPlot software (Jandel) .
  • the binding affinities for the compounds of Formula I towards the NPY]_ receptor are expressed as IC50 values and are less than 10 micromolar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)

Abstract

L'invention concerne des composés de la formule (I) dans laquelle Ar, R1, W et X sont des substituants tels que définis dans la présente invention, ces composés étant: (1) des antagonistes de récepteurs de CRF¿1? et étant donc utiles pour le diagnostic et le traitement de troubles liés au stress tels que le syndrome de stress post-traumatique (PTSD), ainsi que la dépression, les céphalées et l'anxiété; et (2) des antagonistes de récepteurs de neuropeptide Y1, ces composés étant donc utiles pour le traitement de plusieurs troubles cliniques caractérisés par la présence d'un excès de neuropeptide Y.
EP99916294A 1998-04-02 1999-04-01 DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE Withdrawn EP1068207A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8045198P 1998-04-02 1998-04-02
US80451P 1998-04-02
PCT/US1999/007254 WO1999051600A1 (fr) 1998-04-02 1999-04-01 DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO [2,3-b]INDOLE ET 9H-PYRIMIDINO [4,5-b]INDOLE

Publications (1)

Publication Number Publication Date
EP1068207A1 true EP1068207A1 (fr) 2001-01-17

Family

ID=22157476

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99916294A Withdrawn EP1068207A1 (fr) 1998-04-02 1999-04-01 DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE

Country Status (5)

Country Link
EP (1) EP1068207A1 (fr)
JP (1) JP2002510688A (fr)
AU (1) AU3464599A (fr)
CA (1) CA2326606A1 (fr)
WO (1) WO1999051600A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175421A1 (fr) * 1999-04-30 2002-01-30 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003082271A2 (fr) 2002-04-03 2003-10-09 Astrazeneca Ab Composes chimiques
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
CA2552598A1 (fr) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Derives de thienopyrimidine et de thienopyridine substitues par un groupe amino cyclique
RU2367663C2 (ru) 2004-01-06 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные пирролопиримидина и пирролотриазина
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2007161585A (ja) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
EP1814590B2 (fr) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Traitement contre l'obesite ainsi que les maladies associees a l'obesite
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2609388C (fr) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP2330125A3 (fr) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
WO2007024004A1 (fr) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Dérivé phénylpyridone
EP1939194A4 (fr) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd Dérivé de pyridone substitué aromatique bicylique
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (fr) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. dÉrivÉ de diarylcÉtimine
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008151257A2 (fr) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009110510A1 (fr) 2008-03-06 2009-09-11 萬有製薬株式会社 Dérivé d'alkylaminopyridine
WO2009119726A1 (fr) 2008-03-28 2009-10-01 萬有製薬株式会社 Dérivé de diarylméthylamide à activité antagoniste sur un récepteur d'hormone concentrant la mélanine
EP3239170B1 (fr) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2009154132A1 (fr) 2008-06-19 2009-12-23 萬有製薬株式会社 Dérivé de spirodiamine-diarylcétoxime
CA2730603C (fr) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
CA2731358A1 (fr) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. Derive de cycloalkylamine a anneau condense compose de 5/5 ou 5/6 membres
EP2348857B1 (fr) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
AU2009308980B2 (en) 2008-10-30 2013-02-28 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP6140083B2 (ja) 2011-03-15 2017-05-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 三環式ジャイレース阻害薬
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
WO2020167706A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
ATE182148T1 (de) * 1995-05-12 1999-07-15 Neurogen Corp Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9951600A1 *

Also Published As

Publication number Publication date
WO1999051600A1 (fr) 1999-10-14
AU3464599A (en) 1999-10-25
CA2326606A1 (fr) 1999-10-14
JP2002510688A (ja) 2002-04-09

Similar Documents

Publication Publication Date Title
EP1068207A1 (fr) DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE
US6436932B1 (en) Aminoalkyl substituted pyrrolo[3,2-e] pyridine and pyrrolo[2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
US7151109B2 (en) Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators
US6291473B1 (en) Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
US6362186B1 (en) Aminoalkyl substituted 9H-phridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives
CA2520900A1 (fr) Composes de pyrrolo[1,2-b]pyridazine et leur utilisation comme antagonistes des recepteurs du crf1
CA2523072A1 (fr) Composes pyrrolo[1,2-b]pyridaziniques
US7034023B2 (en) Pyrrolo[1,2-B]pyridazine compounds and their uses
US6472402B1 (en) Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US7074791B2 (en) Pyrrolo[1,2-b]pyridazine compounds and their uses
US7056920B2 (en) Pyrrolo[1,2-B]pyridazine compounds and their uses
MXPA00009565A (en) AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES
US20070224636A1 (en) Pyrrolo[1,2b]pyridazine compounds and their uses
US20060166998A1 (en) Pyrrolo[1,2-B]pyridazine compounds and their uses
MXPA00009575A (en) Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives:modulators of crf1 receptors
WO2004092176A1 (fr) Composes de pyrrolo[1,2-b]pyridazine et leurs utilisations
MXPA00009566A (en) Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7, 8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives:crf1 specific ligands

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001031;LT PAYMENT 20001031;LV PAYMENT 20001031;MK PAYMENT 20001031;RO PAYMENT 20001031;SI PAYMENT 20001031

17Q First examination report despatched

Effective date: 20020823

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031210

RTI1 Title (correction)

Free format text: AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-B INDOLE AND 9H-PYRIMIDINO 4,5-B INDOLE DERIVATIVES